Abstract Details

Title Stigma toward Mental and Neurological Disorders Is Common in a Hispanic Community

Topic Ethics, Pain and Palliative Care

Presentation(s) P02 - (-)

Poster/Presentation
Number 003

Objective

Background BACKGROUND: The already high social and economic burden of neuropsychiatric disorders might be further compounded by stigma. Presence, level and variables associated with stigma towards neuropsychiatric diseases are poorly known.

Design/Methods DESIGN/METHODS: Participants in Leon, Nicaragua were asked to view three videos, each followed by a short questionnaire assessing stigma. The videos presented patients with epilepsy, schizophrenia, and dystonia. After completing the three videos questionnaires, participants were given additional information about the patient with dystonia and questionnaire repeated. Variables evaluated included age, gender, education, and knowing people with the same illness.

Results RESULTS: Respondents included 92 participants (65.2% females). Answers that could indicate stigma ranged from 18 to 82.4%, depending upon the illness and question type. Overall, schizophrenia had more stigma (89%) than epilepsy (69.6%) or dystonia (74.2%) (p<0.01). Although highly educated respondents were more likely to know someone with these diseases, level of education was not significantly associated with level of stigma in our sample. Age, gender, or knowing someone with the same illness did not change level of prejudice. Knowing more about who the people in the videos are decreased stigma (McNemar p<0.01), a proof that unjustified preliminary harsh judgment is common.

Conclusions CONCLUSIONS: Stigma toward neuropsychiatric disorders is common in this Hispanic community. In our study, age, gender and level of education did not correspond to differences in prejudice, underlying the complexity of this problem. More studies are needed to evaluate the true implications of stigma toward neuropsychiatric diseases.

Authors/Disclosures
Laila Gharzai PRESENTER	No disclosure on file
	No disclosure on file
Diego Torres-Russotto, MD, FAAN (Miami Neuroscience Institute - Baptist Health South Florida)	Dr. Torres-Russotto has received personal compensation for serving as an employee of Movement Disorders Consulting, Inc. The institution of Dr. Torres-Russotto has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Acorda. The institution of Dr. Torres-Russotto has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for AbbVie. The institution of Dr. Torres-Russotto has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Neurocrine. The institution of Dr. Torres-Russotto has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Revance. The institution of Dr. Torres-Russotto has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Anneal. Dr. Torres-Russotto has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Acorda. Dr. Torres-Russotto has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for IPSEN. Dr. Torres-Russotto has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Teva. The institution of Dr. Torres-Russotto has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for AbbVie. The institution of Dr. Torres-Russotto has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Neurocrine. Dr. Torres-Russotto has received personal compensation in the range of $0-$499 for serving as an officer or member of the Board of Directors for Your Nest Asset Solutions, LLC. Dr. Torres-Russotto has received personal compensation in the range of $0-$499 for serving as an officer or member of the Board of Directors for Bright Future Asset Solutions, LLC.
Anthony Traboulsee, MD (University of British Columbia)	Dr. Traboulsee has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Roche. Dr. Traboulsee has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Sanofi. Dr. Traboulsee has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. Dr. Traboulsee has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi. Dr. Traboulsee has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi. Dr. Traboulsee has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for EMD Serono. Dr. Traboulsee has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Roche. The institution of Dr. Traboulsee has received research support from Roche. The institution of Dr. Traboulsee has received research support from Consortium of MS Centers. The institution of Dr. Traboulsee has received research support from MS Canada. Dr. Traboulsee has received personal compensation in the range of $500-$4,999 for serving as a Workshop Chair with Consortium of MS Centers.

��ɫ��

��ɫ��